DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+9.27%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$423M
AUM Growth
+$423M
(+1.1%)
Cap. Flow
-$19.4M
Cap. Flow
% of AUM
-4.58%
Top 10 Holdings %
Top 10 Hldgs %
48.91%
Holding
89
New
6
Increased
19
Reduced
26
Closed
5
Top Buys
| 1 |
Lexeo Therapeutics
LXEO
|
$2.27M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$1.57M |
| 3 |
IDEAYA Biosciences
IDYA
|
$1.56M |
| 4 |
Ascendis Pharma
ASND
|
$1.28M |
| 5 |
Structure Therapeutics
GPCR
|
$1.27M |
Top Sells
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$7.9M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$4.3M |
| 3 |
Viking Therapeutics
VKTX
|
$4.02M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$2.51M |
| 5 |
TSVT
2seventy bio
TSVT
|
$1.99M |
Sector Composition
| 1 | Healthcare | 86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Alector
ALEC
$282M
| $4.25M | 1.01% |
912,928
| – | – |
|
27
Arcus Biosciences
RCUS
$1.24B
| $3.93M | 0.93% |
256,717
+3,500
| +1% | +$53.5K |
|
28
Galapagos
GLPG
$2.06B
| $3.75M | 0.89% |
130,175
| – | – |
|
29
Insulet
PODD
$24.2B
| $3.7M | 0.87% |
15,900
| – | – |
|
30
Alkermes
ALKS
$4.95B
| $3.38M | 0.8% |
120,700
| – | – |
|
31
Larimar Therapeutics
LRMR
$337M
| $3.24M | 0.76% |
494,274
-145,700
| -23% | -$954K |
|
32
Perspective Therapeutics
CATX
$251M
| $3.07M | 0.73% |
230,322
-1,312
| -0.6% | -$17.5K |
|
|
TSVT
33
DELISTED
2seventy bio
TSVT
| $2.97M | 0.7% |
630,029
-420,680
| -40% | -$1.99M |
|
|
SLRN
34
DELISTED
ACELYRIN
SLRN
| $2.97M | 0.7% |
602,894
-90,715
| -13% | -$447K |
|
35
Allogene Therapeutics
ALLO
$249M
| $2.94M | 0.69% |
1,050,118
+445,018
| +74% | +$1.25M |
|
36
Aquestive Therapeutics
AQST
$478M
| $2.94M | 0.69% |
589,561
+59,561
| +11% | +$297K |
|
37
Century Therapeutics
IPSC
$40.4M
| $2.91M | 0.69% |
1,704,232
| – | – |
|
38
Astria Therapeutics
ATXS
$394M
| $2.8M | 0.66% |
254,165
-20,000
| -7% | -$220K |
|
|
BCYC
39
Bicycle Therapeutics
BCYC
$492M
| $2.77M | 0.65% |
122,200
| – | – |
|
40
Stoke Therapeutics
STOK
$1.08B
| $2.55M | 0.6% |
207,427
| – | – |
|
|
BWAY
41
Brainsway
BWAY
$296M
| $2.32M | 0.55% |
251,346
-46,309
| -16% | -$428K |
|
|
42
Lexeo Therapeutics
LXEO
$266M
| $2.27M | 0.54% |
+250,583
| New | +$2.27M |
|
43
Accuray
ARAY
$165M
| $2.2M | 0.52% |
1,222,358
| – | – |
|
44
ARS Pharmaceuticals
SPRY
$1.08B
| $2.15M | 0.51% |
148,294
-90,900
| -38% | -$1.32M |
|
45
Inogen
INGN
$213M
| $2.03M | 0.48% |
208,790
| – | – |
|
|
CNTA
46
Centessa Pharmaceuticals
CNTA
$2.13B
| $1.92M | 0.45% |
120,351
-2,531
| -2% | -$40.5K |
|
47
Mineralys Therapeutics
MLYS
$1.94B
| $1.77M | 0.42% |
146,500
+27,500
| +23% | +$333K |
|
|
AUTL
48
Autolus Therapeutics
AUTL
$383M
| $1.77M | 0.42% |
486,667
+140,000
| +40% | +$508K |
|
49
Immatics
IMTX
$662M
| $1.65M | 0.39% |
145,000
| – | – |
|
|
ITOS
50
DELISTED
iTeos Therapeutics
ITOS
| $1.65M | 0.39% |
161,584
+17,224
| +12% | +$176K |
|